Skip to main content

Table 1 Characteristics of the studies included in the network meta-analysis

From: Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis

No. References Year Region No. of patients Age (years) % Women BMI (kg/m2) Body weight (kg) Duration of DM (years) HbA1c (%) Hypertension (%) Dyslipidemia (%) Prior CVD (%) Comparison OADs dose (mg/day) Basic treatment Study duration (weeks) LVM (g) or LVMI (g/m2)
1 Yamada et al. [17] 2017 Japan 115 69 35 24.8 NR NR 6.9 76 70 0 Sitagliptin vs. conventional Sitagliptin, 25 or 50; conventional, α-glucosidase inhibitor/glinide/metformin/sulfonylurea/pioglitazone Diet + exercise 96 96.2 (g/m2)
2 Oe et al. [18] 2015 Japan 77 66 35 25.7 NR 3 NR 80 10 5 Sitagliptin vs. voglibose Sitagliptin,50; voglibose, 0.6 Diet + exercise 24 85 (g/m2)
3 McGavock et al. [27] 2012 US 49 55 52 34 92 10.7 7.7 78 65 8 Rosiglitazone vs. placebo Rosiglitazone, 8 Diet + exercise 24 153 (g)
4 Naka et al. [28] 2010 Greece 81 64 72 NR 74.2 9 7.9 NR NR 0 Pioglitazone vs. conventional Pioglitazone, 30; conventional, metformin/sulfonylurea Metformin and/or sulfonylurea 24 118.1 (g/m2)
5 McGuire et al. [29] 2010 US 108 55 38 34 97 8.7 7.2 74 75 37 Rosiglitazone vs. placebo Rosiglitazone, 8 Diet + exercise 24 76 (g/m2)
6 Pala et al. [30] 2010 Turkey 40 55 60 33 NR 4.4 8.4 65 60 0 Rosiglitazone vs. pioglitazone Rosiglitazone, 8; pioglitazone, 30 Metformin and/or sulfonylurea 16 136 (g/m2)
7 van der Meer et al. [19] 2009 Netherlands 71 56 NR 29.3 NR NR 7 NR NR 0 Pioglitazone vs. metformin Pioglitazone, 30; metformin, 2000 Diet + exercise 24 107 (g)
8 Giles et al. [31] 2008 US 518 63 33 29.7 NR 11.6 8.9 NR NR 100 Pioglitazone vs. glyburide Pioglitazone, 30; glyburide, 10 Metformin and/or sulfonylurea 24 NR
9 Lee et al. [14]. 2007 Taiwan 108 63 44 26.6 NR 11 8.3 74 NR 0 Glyburide vs. gliclazide Glyburide, 5; gliclazide, 80 Diet + exercise 24 219 (g)
10 Pan et al. [32] 2006 Taiwan 40 63 52 27 NR 12 8.1 76 NR 0 Glibenclamide vs. gliclazide Glibenclamide, 5; gliclazide, 80 Glibenclamide 24 120 (g/m2)
11 Sutton et al. [33] 2002 US 203 55 25 NR 86.2 5.3 9.1 NR NR 0 Glyburide vs. rosiglitazone Glyburide, 10; rosiglitazone, 8 Diet + exercise 52 75.5 (g/m2)
  1. Unless indicated otherwise, data are shown as mean values
  2. DM diabetes mellitus, BMI body mass index, OADs oral antidiabetic drugs, LVM left ventricular mass, NR not reported